<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04090658</url>
  </required_header>
  <id_info>
    <org_study_id>209699</org_study_id>
    <nct_id>NCT04090658</nct_id>
  </id_info>
  <brief_title>A Study to Test GlaxoSmithKline's (GSK) Respiratory Syncytial Virus RSV Candidate Vaccine's Safety and Immune Response in Japanese Older Adults</brief_title>
  <official_title>Phase I, Observer-blind, Safety, Reactogenicity and Immunogenicity Study of GSK's Respiratory Syncytial Virus (RSV) Vaccine GSK3844766A in Japanese Subjects Aged 60-80 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of 2
      doses of GSK Biologicals' RSV candidate vaccine adjuvanted with AS01B for the prevention of
      lower respiratory tract diseases caused by RSV in ethnic Japanese adults 60-80 years of age.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 25, 2019</start_date>
  <completion_date type="Anticipated">January 8, 2021</completion_date>
  <primary_completion_date type="Actual">January 10, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with solicited local adverse events (AEs) after first dose of vaccination</measure>
    <time_frame>During a 7-day follow-up period (i.e. on the day of vaccination and 6 subsequent days) after first dose of vaccination</time_frame>
    <description>Assessed solicited local AEs are: Pain at injection site; Redness at injection site and Swelling at injection site. Any redness/swelling is scored as injection site redness/swelling with a diameter larger than (&gt;) 20 millimeters (mm).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with solicited local adverse events (AEs) after second dose of vaccination</measure>
    <time_frame>During a 7-day follow-up period (i.e. on the day of vaccination and 6 subsequent days) after second dose of vaccination</time_frame>
    <description>Assessed solicited local AEs are: Pain at injection site; Redness at injection site and Swelling at injection site. Any redness/swelling is scored as injection site redness/swelling with a diameter larger than (&gt;) 20 millimeters (mm).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with solicited general AEs after first dose of vaccination</measure>
    <time_frame>During a 7-day follow-up period (i.e. on the day of vaccination and 6 subsequent days) after first dose of vaccination</time_frame>
    <description>Assessed solicited general AEs solicited are: Fatigue; Fever (any temperature greater than or equal to 38.0 °C - the preferred location for measuring temperature being the oral cavity); Gastrointestinal symptoms including nausea, vomiting, diarrhea and/or abdominal pain; Headache; Myalgia; Shivering and Arthralgia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with solicited general AEs after second dose of vaccination</measure>
    <time_frame>During a 7-day follow-up period (i.e. on the day of vaccination and 6 subsequent days) after second dose of vaccination</time_frame>
    <description>Assessed solicited general AEs solicited are: Fatigue; Fever (any temperature greater than or equal to 38.0 °C - the preferred location for measuring temperature being the oral cavity); Gastrointestinal symptoms including nausea, vomiting, diarrhea and/or abdominal pain; Headache; Myalgia; Shivering and Arthralgia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with unsolicited AEs after first dose of vaccination</measure>
    <time_frame>During a 30-day follow-up period (i.e., on the day of vaccination and 29 subsequent days) after first dose of vaccination</time_frame>
    <description>An unsolicited AE is any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is to be reported as an unsolicited AE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with unsolicited AEs after second dose of vaccination</measure>
    <time_frame>During a 30-day follow-up period (i.e., on the day of vaccination and 29 subsequent days) after second dose of vaccination</time_frame>
    <description>An unsolicited AE is any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is to be reported as an unsolicited AE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects presenting hematological and biochemical abnormalities after first vaccine dose when compared to Day 1</measure>
    <time_frame>At 7 days after the first vaccine dose (Day 8)</time_frame>
    <description>Assessed hematological laboratory parameters include erythrocytes, white blood cells [WBC] and differential count, platelets count and hemoglobin level. Biochemical laboratory parameters include alanine aminotransferase [ALT], aspartate aminotransferase [AST], creatinine, blood urea nitrogen [BUN] and uric acid., Abnormalities reported when comparing Day 1 (pre-vaccination dose 1) and Day 8 haematological and biochemical laboratory results are tabulated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects presenting hematological and biochemical abnormalities after second vaccine dose, when compared to Day 61</measure>
    <time_frame>At 7 days after the second vaccine dose (Day 68)</time_frame>
    <description>Assessed hematological laboratory parameters include erythrocytes, white blood cells [WBC] and differential count, platelets count and hemoglobin level. Biochemical laboratory parameters include alanine aminotransferase [ALT], aspartate aminotransferase [AST], creatinine, blood urea nitrogen [BUN] and uric acid., Abnormalities reported when comparing Day 61 (pre-vaccination dose 2) and Day 68 haematological and biochemical laboratory results are tabulated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects presenting hematological and biochemical abnormalities after second vaccine dose, when compared to Day 1</measure>
    <time_frame>At 67 days after the first vaccine dose (Day 68)</time_frame>
    <description>Assessed hematological laboratory parameters include erythrocytes, white blood cells [WBC] and differential count, platelets count and hemoglobin level. Biochemical laboratory parameters include alanine aminotransferase [ALT], aspartate aminotransferase [AST], creatinine, blood urea nitrogen [BUN] and uric acid., Abnormalities reported when comparing Day 1 (pre-vaccination dose 1) and Day 68 haematological and biochemical laboratory results are tabulated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with any Grade 3 non-serious AEs (solicited and unsolicited) after first dose of vaccination</measure>
    <time_frame>During a 30-day follow-up period (i.e., on the day of vaccination and 29 subsequent days) after first dose of vaccination</time_frame>
    <description>A Grade 3 AE is any AE assessed as severe, i.e. which prevents normal, everyday activities. In adults, such an AE would, for example, prevent attendance at work and would necessitate the administration of corrective therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with any Grade 3 non-serious AEs (solicited and unsolicited) after second dose of vaccination</measure>
    <time_frame>During a 30-day follow-up period (i.e., on the day of vaccination and 29 subsequent days) after second dose of vaccination</time_frame>
    <description>A Grade 3 AE is any AE assessed as severe, i.e. which prevents normal, everyday activities. In adults, such an AE would, for example, prevent attendance at work and would necessitate the administration of corrective therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with any Serious Adverse Events (SAEs) up to 30 days after the second vaccination</measure>
    <time_frame>From Day 1 up to 30 days after the second vaccination (Day 91)</time_frame>
    <description>A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalization or results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with any potential immune-mediated diseases (pIMDs) up to 30 days after the second vaccination</measure>
    <time_frame>From Day 1 up to 30 days after the second vaccination (Day 91)</time_frame>
    <description>pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Humoral immune response with respect to components of the investigational vaccine in terms of neutralizing antibody titers against RSV-A</measure>
    <time_frame>At pre-vaccination (Day 1), 30 days post-Dose 1 (Day 31), on the day of second vaccination (Day 61) and 30 days post-Dose 2 (Day 91)</time_frame>
    <description>Serological assays for the determination of functional antibodies against RSV-A are performed by neutralization assay. The corresponding antibody titers are expressed in Estimated Dose: serum dilution giving a 60% reduction of the signal compared to a control without serum (ED60). The cut-off value will be defined in the statistical analysis plan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Humoral immune response with respect to components of the investigational vaccine in terms of RSVPreF3-specific Immunoglobulin G (IgG) antibody concentrations</measure>
    <time_frame>At pre-vaccination (Day 1), 30 days post-Dose 1 (Day 31), on the day of second vaccination (Day 61) and 30 days post-Dose 2 (Day 91)</time_frame>
    <description>The detection and the quantification of total IgG antibodies directed against RSVPreF3 in human serum samples are based on an indirect enzyme-linked immunosorbent assay (ELISA). The corresponding antibody concentration, is expressed in arbitrary ELISA Laboratory Units per milliliter (ELU/mL). The cut-off value will be defined in the statistical analysis plan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with any SAEs, up the end of follow-up (Month 14)</measure>
    <time_frame>From Day 1 up to the end of follow-up (Month 14)</time_frame>
    <description>A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects reporting pIMDs up to the end of follow-up (Month 14)</measure>
    <time_frame>From Day 1 up to the end of follow-up (Month 14)</time_frame>
    <description>pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with RSV-associated respiratory tract infection (RTI) in the combined nasal and throat swabs collected during the assessment visit for potential RSV-RTI during the RSV seasons, up to the end of follow-up</measure>
    <time_frame>During the RSV seasons from Day 1 to Month 14</time_frame>
    <description>For identified RTI cases under active or passive surveillance, the potential RSV infection is assessed and confirmed by quantitative reverse transcription polymerase chain reaction (qRT-PCR) testing of swabs. The results are expressed in Copies/milliliter (copies/mL).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Respiratory Syncytial Virus Infections</condition>
  <arm_group>
    <arm_group_label>Group RSV_PreF3_AS01B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects aged 60 to 80 years receiving 2 doses of the investigational adjuvanted RSV_PreF3 vaccine (GSK3844766A), at Days 1 and 61, by intramuscular (IM) injection into the deltoid region of the non-dominant arm preferably.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects aged 60 to 80 years receiving 2 doses of placebo as control, at Days 1 and 61, by IM injection into the deltoid region of the non-dominant arm preferably.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RSV_PreF3 Vaccine (GSK3844766A) adjuvanted with AS01B</intervention_name>
    <description>Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the non-dominant arm preferably.</description>
    <arm_group_label>Group RSV_PreF3_AS01B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the non-dominant arm preferably.</description>
    <arm_group_label>Group Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who, in the opinion of the investigator, can and will comply with the
             requirements of the protocol.

          -  Written informed consent obtained from the subject prior to performance of any study
             specific procedure.

          -  A male or female between, and including, 60 and 80 years of age at the time of the
             first vaccination.

          -  Subjects with residence status allowing free mixing with general community or in an
             assisted-living facility that provides minimal assistance, such that the subject is
             primarily responsible for self-care and activities of daily living, may be enrolled.

          -  Japanese ethnic origin (defined as having been born in Japan with four ethnic Japanese
             grandparents and able to speak Japanese).

          -  Subject satisfying screening requirements.

        Exclusion Criteria:

        Medical conditions

          -  Any medical condition that in the judgment of the investigator would make IM injection
             unsafe.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical examination (no laboratory testing required).

          -  History of any reaction or hypersensitivity likely to be exacerbated by any component
             of the vaccine.

          -  Hypersensitivity to latex.

          -  Serious or unstable chronic illness. Patients with chronic stable conditions with or
             without specific treatment, such as diabetes, hypertension or cardiac disease, are
             allowed to participate in this study.

          -  Any other condition that, in the opinion of the investigator, might interfere with the
             evaluations required by the study.

          -  History of any neurological disorders or seizures.

          -  Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal
             functional abnormality, as determined by the investigator based on medical history,
             physical examination or laboratory screening tests.

          -  Hepatomegaly, right upper quadrant abdominal pain or tenderness.

          -  Significant underlying illness that in the opinion of the investigator would be
             expected to prevent completion of the study.

          -  Lymphoproliferative disorder and malignancy within 5 years.

          -  At screening: Hematology parameters (complete blood cell count [red blood cells, WBC],
             white blood cells differential count [lymphocytes, neutrophils and eosinophils],
             platelets count or hemoglobin level) and/or biochemistry parameters (creatinine, blood
             urea nitrogen or liver enzymes [ALT or AST]) outside the normal laboratory ranges,
             unless the laboratory abnormalities are considered not clinically significant by the
             investigator.

        Prior/Concomitant therapy

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccine during the period starting 30 days before the first dose of study
             vaccine (Day -29 to Day 1), or planned use during the study period.

          -  Planned administration/administration of a vaccine not foreseen by the study protocol
             in the period starting 30 days before the first dose and ending 30 days after the last
             dose of study vaccine administration, with the exception of inactivated and subunit
             influenza vaccines which can be administered up to 14 days before or from 30 days
             after each study vaccination.

          -  Previous vaccination with an RSV vaccine.

          -  Known previous administration of a vaccine containing MPL, QS-21 and/or MF59.

          -  Planned administration of GSK's Herpes Zoster vaccine marketed as Shingrix or an
             adjuvanted recombinant varicella zoster virus envelope gE subunit vaccine [HZ/su]
             within 180 days after the second dose of the study vaccine.

          -  Chronic administration (defined as more than 14 consecutive days in total) of
             immunosuppressants or other immune-modifying drugs during the period starting 6 months
             prior to the first vaccine dose. For corticosteroids, this will mean prednisone (≥ 20
             mg/day, or equivalent). Inhaled and topical steroids are allowed.

          -  Administration of long-acting immune-modifying drugs or planned administration at any
             time during the study period.

          -  Administration of immunoglobulins and/or any blood products during the period starting
             3 months before the first dose of study vaccine or planned administration during the
             study period.

        Prior/Concurrent clinical study experience

        • Concurrently participating in another clinical study, at any time during the study
        period, in which the subject has been or will be exposed to an investigational or a
        non-investigational vaccine/product (pharmaceutical product or device).

        Other exclusions

          -  History of chronic alcohol consumption and/or drug abuse as deemed by the investigator
             to render the potential subject unable/unlikely to provide accurate safety reports.

          -  Body mass index greater than 40 kg/m^2.

          -  Planned move to a location that will prohibit participating in the trial until study
             end.

          -  Bedridden subjects.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-0025</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>September 12, 2019</study_first_submitted>
  <study_first_submitted_qc>September 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2019</study_first_posted>
  <last_update_submitted>January 21, 2020</last_update_submitted>
  <last_update_submitted_qc>January 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints of the study</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

